Dithiolethiones inhibit NF-κB activity via covalent modification in human estrogen receptor-negative breast cancer

Cancer Research

Volumn 72, Issue 9, 2012, Pages 2394-2404

  Switzer, Christopher H ^a   Cheng, Robert Y S ^a   Ridnour, Lisa A ^a   Murray, Margaret C ^a   Tazzari, Valerio ^b   Sparatore, Anna ^b   Del Soldato, Piero ^c   Hines, Harry B ^d   Glynn, Sharon A ^a,e   Ambs, Stefan ^a   Wink, David A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MILAN   (Italy)

^c Sulfidris   (Italy)

^d UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^e NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DITHIOLETHIONE DERIVATIVE; ESTROGEN RECEPTOR; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; PHOSPHOPROTEIN PHOSPHATASE 2A; UNCLASSIFIED DRUG; UROKINASE; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; COVALENT BOND; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSCRIPTION INITIATION; TUMOR VOLUME; TUMOR XENOGRAFT;

ACTIVE TRANSPORT, CELL NUCLEUS; ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL NUCLEUS; FEMALE; HUMANS; I-KAPPA B KINASE; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; RECEPTORS, ESTROGEN; THIONES; TRANSCRIPTIONAL ACTIVATION;

EID: 84860522931     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-3115     Document Type: Article

References (32)

1. Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999;18:6938-47.
2. Karin M, Cao Y, Greten FR, Li Z-W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-10. (Pubitemid 37328783)
3. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004;6:203-8.
4. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge GW Jr. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 1997;17:3629-39. (Pubitemid 27281838)
5. Huber MA, Azoitei N, Baumann B, Grunert S, Sommer A, Pehamberger H, et al. NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 2004;114:569-81. (Pubitemid 39572107)
6. Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB, et al. NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci U S A 2004;101:10137-42. (Pubitemid 38891208)
7. Glynn S, Prueitt R, Ridnour L, Boersma B, Dorsey T, Wink D, et al. COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancer.BMCCancer 2010;10:626.
8. Glynn SA, Boersma BJ, Dorsey TH, Yi M, Yfantis HG, Ridnour LA, et al. Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. J Clin Invest 2010;120:3843-54.
9. Orlowski RZ, Baldwin AS. NF-kappaBas a therapeutic target in cancer. Trends Mol Med 2002;8:385-9.
10. Gupta SC, Sundaram C, Reuter S, Aggarwal BB. Inhibiting NF-κB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta 2010;1799:775-87.
11. Biswas DK, Dai S-C, Cruz A, Weiser B, Graner E, Pardee AB. The nuclear factor kappa B (NF-kappa B): a potential therapeutic target for estrogen receptor negative breast cancers. Proc Natl Acad Sci U S A 2001;98:10386-91. (Pubitemid 32803029)
12. Li L, Rossoni G, Sparatore A, Lee LC, Del Soldato P, Moore PK. Anti-inflammatory and gastrointestinal effects of a novel diclofenac derivative. Free Radic Biol Med 2007;42:706-19. (Pubitemid 46205152)
13. LamS, MacAulay C, le Riche JC, Dyachkova Y, Coldman A, Guillaud M, et al. A randomized phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia. J Natl Cancer Inst 2002;94:1001-9. (Pubitemid 34814729)
14. Wang J-S, Shen X, He X, Zhu Y-R, Zhang B-C, Wang J-B, et al. Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People's Republic of China. J Natl Cancer Inst 1999;91:347-54. (Pubitemid 29102334)
15. Kwak M-K, Egner PA, Dolan PM, Ramos-Gomez M, Groopman JD, Itoh K, et al. Role of phase 2 enzyme induction in chemoprotection by dithiolethiones. Mutat Res 2001;480-481:305-15. (Pubitemid 32744837)
16. Lee J-S, Surh Y-J. Nrf2 as a novel molecular target for chemoprevention. Cancer Lett 2005;224:171-84. (Pubitemid 40725839)
17. Bass SE, Sienkiewicz P, MacDonald CJ, Cheng RYS, Sparatore A, Del Soldato P, et al. Novel dithiolethione-modified nonsteroidal anti-inflammatory drugs in human hepatoma HepG2 and colon LS180 cells. Clin Cancer Res 2009;15:1964-72.
18. Switzer CH, Ridnour LA, Cheng RYS, Sparatore A, Del Soldato P, Moody TW, et al. Dithiolethione compounds inhibit Akt signaling in human breast and lung cancer cells by increasing PP2A activity. Oncogene 2009;28:3837-46.
19. Isenberg JS, Jia Y, Field L, Ridnour LA, Sparatore A, Del Soldato P, et al. Modulation of angiogenesis by dithiolethione-modified NSAIDs and valproic acid. Br J Pharmacol 2007;151:142-51. (Pubitemid 46676006)
20. Moody TW, Switzer C, Santana-Flores W, Ridnour LA, Berna M, Thill M, et al. Dithiolethione modified valproate and diclofenac increase E-cadherin expression and decrease proliferation of non-small cell lung cancer cells. Lung Cancer 2010;68:154-60.
21. Nho CW, O'Dwyer PJ. NF-κB activation by the chemopreventive dithiolethione oltipraz is exerted through stimulation of MEKK3 signaling. J Biol Chem 2004;279:26019-27. (Pubitemid 38798744)
22. Sen CK, Traber KE, Packer L. Inhibition of NF-[kappa]B activation in human T-cell lines by anetholdithiolthione. Biochem Biophys Res Commun 1996;218:148-53.
23. Fu DX, Kuo YL, Liu BY, Jeang KT, Giam CZ. Human T-lymphotropic virus type I tax activates I-kappa B kinase by inhibiting I-kappa B kinase-associated serine/threonine protein phosphatase 2A. J Biol Chem 2003;278:1487-93.
24. Sliva D, Rizzo MT, English D. Phosphatidylinositol 3-kinase and NF-κB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator. J Biol Chem 2002;277:3150-7. (Pubitemid 34953176)
25. Zajchowski DA, Bartholdi MF, Gong Y, Webster L, Liu H-L, Munishkin A, et al. Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res 2001;61:5168-78. (Pubitemid 32681550)
26. Zhang Y, Munday R. Dithiolethiones for cancer chemoprevention: where do we stand? Mol Cancer Ther 2008;7:3470-9.
27. Lee M, Schwab C, Yu S, McGeer E, McGeer PL. Astrocytes produce the antiinflammatory and neuroprotective agent hydrogen sulfide. Neurobiol Aging 2009;30:1523-34.
28. Zhi L, Ang AD, Zhang H, Moore PK, Bhatia M. Hydrogen sulfide induces the synthesis of proinflammatory cytokines in human monocyte cell line U937 via the ERK-NF-κB pathway. J Leukoc Biol 2007;81:1322-32. (Pubitemid 46702052)
29. Toledano MB, Leonard WJ. Modulation of transcription factor NF-kappa Bbinding activity by oxidation-reduction in vitro. ProcNatl Acad Sci U S A 1991;88:4328-32. (Pubitemid 21914533)
30. Pande V, Sousa SF, Ramos MJ. Direct covalent modification as a strategy to inhibit nuclear factor-kappa B. Curr Med Chem 2009;16:4261-73.
31. Farina AR, Tacconelli A, Vacca A, Maroder M, Gulino A, Mackay AR. Transcriptional up-regulation of matrix metalloproteinase-9 expression during spontaneous epithelial to neuroblast phenotype conversion by SK-N-SH neuroblastoma cells, involved in enhanced invasivity, depends upon GT-box and nuclear factor kappaB elements. Cell Growth Differ 1999;10:353-67. (Pubitemid 29242601)
32. Bhat-Nakshatri P, Newton TR, Goulet R, Nakshatri H. NF-κB activation and interleukin 6 production in fibroblasts by estrogen receptor-negative breast cancer cell-derived interleukin 1b. Proc Natl Acad SciUSA 1998;95:6971-6. (Pubitemid 28278091)